Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
AZD-3427: A Comprehensive Analysis of a Novel Long-Acting Relaxin Mimetic for Heart Failure and Pulmonary Hypertension
Executive Summary
AZD-3427 is a first-in-class, investigational, long-acting relaxin mimetic being developed by AstraZeneca as a potential therapy for heart failure (HF) and associated pulmonary hypertension (PH). Engineered as a human recombinant Fc fusion protein, AZD-3427 is designed to overcome the critical limitation of its short-acting predecessors—a short plasma half-life—thereby enabling chronic subcutaneous administration for sustained therapeutic effect. The drug selectively targets the relaxin family peptide receptor 1 (RXFP1), a G-protein coupled receptor whose activation mediates a cascade of beneficial pleiotropic effects, including vasodilation, and anti-inflammatory and anti-fibrotic actions. These mechanisms are highly relevant to the complex pathophysiology of cardiorenal disease.
The development of AZD-3427 represents a significant strategic pivot, shifting the therapeutic paradigm for relaxin-based therapies from acute, in-hospital treatment to chronic, outpatient disease modification. This strategy is informed by the mixed results of earlier trials with short-acting relaxin analogues, which suggested that sustained receptor engagement may be necessary to alter the long-term trajectory of heart failure. Preclinical studies in non-human primates have demonstrated that prolonged administration of AZD-3427 leads to significant improvements in cardiac function. A first-in-human Phase 1a/b study confirmed a favorable safety, tolerability, and pharmacokinetic profile, with a terminal half-life of 13-14 days in heart failure patients and early signals of positive hemodynamic and renal effects.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/09/25 | Phase 1 | Recruiting | |||
2023/02/21 | Phase 2 | Active, not recruiting | |||
2021/05/18 | Phase 1 | Withdrawn | |||
2020/11/16 | Phase 1 | Completed | |||
2018/02/28 | Phase 2 | Active, not recruiting | |||
2008/06/25 | Phase 3 | Completed | |||
2007/08/27 | Phase 2 | Completed | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | ||
2005/11/29 | Phase 2 | Completed | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | ||
1999/10/19 | Phase 2 | Completed | National Center for Research Resources (NCRR) |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.